LONDON - Gilead Sciences Inc expects supply of its potential COVID-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 m
illion.
Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial. But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms healthcare systems around the world.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Telkom suspends dividend policy for three years over spectrum auctionGroup has paid a final dividend for its year to end-March, but eyes future capex
Read more »
Telkom suspends dividend policy for three years over spectrum auctionGroup has paid a final dividend for its year to end-March, but eyes future capex
Read more »
How can a watertight case like this be dismissed? asks Ayanda Simelane's momHow can a watertight case like this be dismissed? asks Ayanda Simelane's mom Two years after 19-year-old Ayanda Simelane was hacked to death allegedly by her boyfriend, her family were denied closure last week when the long-awaited case was withdrawn.
Read more »
Plans for South Africa cricket return shelvedThe statement said a new date would be announced 'in due course'.
Read more »